A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Overview
- Phase
- Phase 1
- Intervention
- CART-TnMUC1
- Conditions
- Non-Small Cell Lung Cancer
- Sponsor
- Kite, A Gilead Company
- Enrollment
- 16
- Locations
- 10
- Primary Endpoint
- Cohort Expansion: Objective Response in solid tumors
- Status
- Terminated
- Last Updated
- 2 years ago
Overview
Brief Summary
Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART- TnMUC1 cells).
Detailed Description
The Dose Escalation phase of the study is designed to identify the dose and regimen of CART-TnMUC1 cells that can be safely administered intravenously following the lymphodepletion (LD) regimen to patients with (1) advanced TnMUC1+ solid tumors (triple negative breast cancer, epithelial ovarian cancer, pancreatic cancer, and non-small cell lung cancer) and (2) advanced TnMUC1+ multiple myeloma in a parallel two-arm dose escalation study. The Dose Escalation phase is anticipated to enroll approximately 40 patients. The Expansion phase of the study is designed to assess the preliminary efficacy of CART-TnMUC1 cells administered intravenously to patients with TnMUC1+ solid tumors. The Expansion phase is anticipated to enroll approximately 72 patients (18 patients per each tumor indication).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Confirmed diagnosis of metastatic treatment-resistant ovarian cancer (including cancers of the fallopian tube), pancreatic adenocarcinoma, hormone receptor (HR)-negative and HER2-negative (triple negative) breast cancer (TNBC) or non-small cell lung cancer (NSCLC), or relapsed/refractory multiple myeloma
- •Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
- •Prior therapies as defined by tumor type:
- •Multiple myeloma: relapsed or refractory disease previously treated with or intolerant to at least three different lines of therapy that contained at least one of the following drug classes: proteasome inhibitor, an immune modulatory drug, alkylators, CD38 monoclonal antibody and glucocorticoids. Patients must be at least 90 days since autologous stem cell transplant
- •NSCLC: i.) Patients without driver mutations must have received standard therapy, including both checkpoint inhibition and platinum-based chemotherapy or be intolerant of these standard therapies ii.) Patients with driver mutations must have received or be intolerant to prior targeted therapy directed at the specific identified mutations in addition to the standard chemotherapy classes
- •Pancreatic adenocarcinoma: disease progression following at least one standard of care systemic chemotherapy for metastatic or unresectable disease or be intolerant of these standard therapies
- •TNBC: ER and/or PR \< or =10%, HER2 negative and experienced disease progression following at least one prior systemic anti-cancer therapy regimen as part of their treatment for management of metastatic breast cancer or be intolerant to these standard therapies
- •Ovarian: platinum-resistant (progression of disease by either CA-125, clinical or radiographic assessment within 6 months of last platinum-based chemotherapy ) and must have received at least two prior lines of therapy for metastatic ovarian cancer, including at least one prior line of therapy including a platinum-containing regimen or be intolerant of these standard therapies
- •Evaluable disease as defined by tumor type
- •TnMUC1+ disease, determined by centrally tested TnMUC1 expression in a prior or archival tumor biopsy
Exclusion Criteria
- •Active invasive cancer other than the proposed cancers included in the study
- •Current treatment with systemic high-dose corticosteroids (defined as a dose greater than the equivalent of prednisone 10 mg/day)
- •Active autoimmune disease (including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease or multiple sclerosis) or have a history of severe autoimmune disease requiring prolonged immunosuppressive therapy (any immunosuppressive therapy should have been stopped within 6 weeks prior to screening visit)
- •Current human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV) infections
- •Other active or uncontrolled medical or psychiatric condition that would preclude participation in the opinion of the Sponsor or Principal Investigator
- •Prior allogeneic stem cell transplant
- •Active and untreated central nervous system (CNS) malignancy
- •History of severe infusion reaction to monoclonal antibodies or biological therapies, or to study product excipients that would preclude the patient safely receiving CART-TnMUC1 cells
- •Active or recent (within the past 6 months prior to apheresis) cardiovascular disease, defined as (1) New York Heart Association (NYHA) Class III or IV heart failure, (2) unstable angina or (3) a history of recent (within 6 months) myocardial infarction or sustained (\> 30 second) ventricular tachyarrhythmias, or (4) cerebrovascular accident
- •Have inadequate venous access for or contraindications for the apheresis procedure
Arms & Interventions
Dose Escalation Arm1: Solid Tumors
Intravenous CART-TnMUC1 cells for patients with TnMUC1+ treatment-resistant ovarian cancer (including cancers of the fallopian tube), pancreatic ductal adenocarcinoma, hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative (triple negative) breast cancer and non-small cell lung cancer
Intervention: CART-TnMUC1
Dose Escalation Arm1: Solid Tumors
Intravenous CART-TnMUC1 cells for patients with TnMUC1+ treatment-resistant ovarian cancer (including cancers of the fallopian tube), pancreatic ductal adenocarcinoma, hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative (triple negative) breast cancer and non-small cell lung cancer
Intervention: Cyclophosphamide
Dose Escalation Arm1: Solid Tumors
Intravenous CART-TnMUC1 cells for patients with TnMUC1+ treatment-resistant ovarian cancer (including cancers of the fallopian tube), pancreatic ductal adenocarcinoma, hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative (triple negative) breast cancer and non-small cell lung cancer
Intervention: Fludarabine
Dose Escalation Arm 2: Multiple Myeloma
Intravenous CART-TnMUC1 cells for patients with TnMUC1+ relapsed/refractory multiple myeloma
Intervention: CART-TnMUC1
Dose Escalation Arm 2: Multiple Myeloma
Intravenous CART-TnMUC1 cells for patients with TnMUC1+ relapsed/refractory multiple myeloma
Intervention: Cyclophosphamide
Dose Escalation Arm 2: Multiple Myeloma
Intravenous CART-TnMUC1 cells for patients with TnMUC1+ relapsed/refractory multiple myeloma
Intervention: Fludarabine
Outcomes
Primary Outcomes
Cohort Expansion: Objective Response in solid tumors
Time Frame: Up to 2 years
Proportion of patients having a confirmed Complete Response (CR) or Partial Response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Dose Escalation: Dose Identification of CART-TnMUC1
Time Frame: Up to 2 years
Incidence of Dose Limiting Toxicity (DLT) in solid tumors and multiple myeloma
Secondary Outcomes
- Preliminary anti-tumor efficacy of CART as assessed by Time to Progression (TTP) in multiple myeloma(Up to 2 years)
- Preliminary anti-tumor efficacy of CART as assessed by Minimal Residual Disease (MRD) in multiple myeloma(Up to 2 years)
- Preliminary anti-tumor efficacy of CART as assessed by Overall Survival (OS) in solid tumors and multiple myeloma(Up to 2 years)
- Preliminary anti-tumor efficacy of CART as assessed by Duration of Response (DOR) in solid tumors and multiple myeloma(Up to 2 years)
- Preliminary anti-tumor efficacy of CART as assessed by Progression Free Survival (PFS) in solid tumors(Up to 2 years)
- Preliminary anti-tumor efficacy of CART as assessed by Objective Response Rate (ORR) in solid tumors and multiple myeloma(Up to 2 years)
- Preliminary anti-tumor efficacy of CART as assessed by Clinical Benefit Rate in solid tumors(Up to 2 years)
- Preliminary anti-tumor efficacy of CART as assessed by Time to Response (TTR) in solid tumors and multiple myeloma(Up to 2 years)
- Peripheral expansion and persistence of CART-TnMUC1 cells in solid tumors and multiple myeloma(Up to 15 years)
- Safety of CART-TnMUC1 in solid tumors and multiple myeloma(Up to 2 years)
- Tolerability of CART-TnMUC1 in solid tumors and multiple myeloma(Up to 2 years)
- Feasibility of CART-TnMUC1 in solid tumors and multiple myeloma(Up to 2 years)